PT  - JOURNAL ARTICLE
AU  - NERICH, VIRGINIE
AU  - BAZAN, FERNANDO
AU  - COMPAGNAT, FANNY
AU  - DOBI, ERION
AU  - VILLANUEVA, CRISTIAN
AU  - CHAIGNEAU, LOÏC
AU  - PERRIN, SOPHIE
AU  - VOIDEY, ALINE
AU  - PIVOT, XAVIER
AU  - LIMAT, SAMUEL
TI  - First-line Bevacizumab plus Taxane-based Chemotherapy for Metastatic Breast Cancer: Cost-minimisation Analysis
DP  - 2012 Aug 01
TA  - Anticancer Research
PG  - 3547--3552
VI  - 32
IP  - 8
4099  - http://ar.iiarjournals.org/content/32/8/3547.short
4100  - http://ar.iiarjournals.org/content/32/8/3547.full
SO  - Anticancer Res2012 Aug 01; 32
AB  - Aim: To carry out a cost minimisation analysis including a comparison of the costs arising from first-line treatment by bevacizumab plus docetaxel (BD) versus bevacizumab plus paclitaxel (BP) of patients with metastatic breast cancer (mBC). Patient and Methods: All consecutive patients with human epidermal growth receptor 2-negative mBC and treated at Besançon University hospital between 2006 and 2010 by a first-line therapy containing bevacizumab plus taxane were retrospectively studied. Economic analysis took into account costs related to drugs, hospitalization and healthcare travel. Results: Progression-free survival difference between the two treatments was insignificant (p-value=0.31). BP treatment was associated with a higher mean total cost than that of BD treatment, €53,093±34,395 versus €60,196±48,766, respectively. Conclusion: Whereas bevacizumab is recommended for first-line treatment of mBC with paclitaxel-based chemotherapy, our study has shown that BD treatment is the most cost-efficient regimen. It could be an attractive option in France, with a potential cost saving of €24,000,000 per year.